TIDMHCM

RNS Number : 2450Z

Hutchmed (China) Limited

12 May 2023

HUTCHMED Announces Board of Directors and Board Committee Membership

Hong Kong, Shanghai & Florham Park, NJ - Friday, May 12, 2023: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM, HKEX: 13) refers to its announcement on May 10, 2023 of the appointment of Professor Solange Peters as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company with effect from the conclusion of the annual general meeting of the Company to be held on May 12, 2023 ("AGM"). The Company today announces that the effective date of such appointments will be deferred until a later date to be announced by the Company.

The Company also announces that Professor Mok Shu Kam, Tony will be appointed as member of the Audit Committee of the Company at the conclusion of the AGM, subject to Professor Mok being re-elected as a Director by the shareholders at the AGM.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/ immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch--med.com or follow us on LinkedIn.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, the risk that current or future appointees to HUTCHMED's board of directors are not e ective in their respective positions, the di iculty in locating and recruiting suitable candidates for its board of directors and the management di iculties which may arise from changes in HUTCHMED's board of directors. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the U.S. Securities and Exchange Commission, on A M and with The Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                            +852 2121 8200 
  Annie Cheng, Vice President                                +1 (973) 306- 4490 
 
Media Enquiries 
  Americas - Brad Miles,                                     +1 (917) 570 7340 (Mobile) / bmiles@s oleburystrat .com 
   Solebury Strategic Communications 
  Europe - Ben Atwell / Alex Shaw,                           +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 
   FTI Consulting                                            545 055 (Mobile) / HUTCHMED@fticonsulting.com 
  Asia - Zhou Yi, Brunswick                                  +852 97 83 6894 (Mobile) / HUTCHMED@brunswickgroup.com 
 
Nominated Advisor 
  Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure 
   Gordon                                                    +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAGPUMGAUPWUMP

(END) Dow Jones Newswires

May 12, 2023 04:30 ET (08:30 GMT)

HUTCHMED China (AQSE:HCM.GB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos HUTCHMED China.
HUTCHMED China (AQSE:HCM.GB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos HUTCHMED China.